Cambridge Trust Co. lowered its holdings in Johnson & Johnson (NYSE:JNJ) by 5.4% in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 294,423 shares of the company’s stock after selling 16,837 shares during the quarter. Johnson & Johnson makes up about 2.7% of Cambridge Trust Co.’s investment portfolio, making the stock its 2nd largest holding. Cambridge Trust Co.’s holdings in Johnson & Johnson were worth $38,950,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the company. Lenox Wealth Advisors Inc. raised its position in shares of Johnson & Johnson by 0.6% in the 2nd quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock worth $116,000 after acquiring an additional 5 shares in the last quarter. Lbmc Investment Advisors LLC raised its position in shares of Johnson & Johnson by 0.4% in the 1st quarter. Lbmc Investment Advisors LLC now owns 3,704 shares of the company’s stock worth $461,000 after acquiring an additional 14 shares in the last quarter. Stratford Consulting LLC raised its position in shares of Johnson & Johnson by 0.6% in the 2nd quarter. Stratford Consulting LLC now owns 2,728 shares of the company’s stock worth $361,000 after acquiring an additional 16 shares in the last quarter. North Point Portfolio Managers Corp OH raised its position in shares of Johnson & Johnson by 0.7% in the 2nd quarter. North Point Portfolio Managers Corp OH now owns 2,923 shares of the company’s stock worth $387,000 after acquiring an additional 20 shares in the last quarter. Finally, Ironwood Investment Management LLC raised its position in shares of Johnson & Johnson by 0.4% in the 2nd quarter. Ironwood Investment Management LLC now owns 5,074 shares of the company’s stock worth $671,000 after acquiring an additional 20 shares in the last quarter. 65.93% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/johnson-johnson-jnj-shares-sold-by-cambridge-trust-co/1701483.html.

JNJ has been the subject of several research reports. UBS AG reissued a “buy” rating and issued a $148.00 target price (up previously from $136.00) on shares of Johnson & Johnson in a research report on Wednesday, July 19th. Credit Suisse Group started coverage on Johnson & Johnson in a research report on Thursday, July 20th. They set an “outperform” rating and a $148.00 price objective for the company. BTIG Research lowered Johnson & Johnson from a “neutral” rating to a “sell” rating and set a $110.00 price objective for the company. in a research report on Friday, July 21st. Atlantic Securities lowered Johnson & Johnson from a “neutral” rating to an “underweight” rating and set a $113.00 price objective for the company. in a research report on Friday, July 21st. Finally, Alembic Global Advisors lowered Johnson & Johnson from a “neutral” rating to an “underweight” rating in a research report on Friday, July 21st. Four equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $143.70.

Johnson & Johnson (JNJ) opened at $139.76 on Tuesday. The stock has a market capitalization of $374,930.72, a price-to-earnings ratio of 19.55, a PEG ratio of 2.84 and a beta of 0.82. Johnson & Johnson has a 52 week low of $109.32 and a 52 week high of $144.35. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.80 by $0.10. The firm had revenue of $19.65 billion for the quarter, compared to the consensus estimate of $19.29 billion. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period last year, the business posted $1.68 EPS. research analysts predict that Johnson & Johnson will post 7.28 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be paid a $0.84 dividend. The ex-dividend date is Monday, November 27th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.40%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 58.33%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.